Go or go go? J&J’s cell therapy heads to the FDA
November approval decisions loom for cilta-cel and Voxzogo, while molnupiravir heads for an advisory panel.
Esmo 2021 movers – a handful of biotech winners emerge
Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.
Vantage Esmo 2021 roundup
Here's a roundup of Vantage's coverage of the 2021 European Society for Medical Oncology congress.
Bayer beefs up discovery work with Vividion buyout
Growing interest in protein degradation helps explain why Bayer had to pay $1.5bn to corner the private group.
Plinabulin blooms at last for Beyondspring
But the vascular disrupting agent’s unexpected success in a cancer indication might not be as resounding as it seems.
Asco 2021 movers – PDS wins, but big pharma reigns
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.